Working… Menu

Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03755947
Recruitment Status : Recruiting
First Posted : November 28, 2018
Last Update Posted : April 26, 2019
Information provided by (Responsible Party):
Grupo Cooperativo de Hemopatías Malignas

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : February 28, 2023